Patent application number | Description | Published |
20090156576 | Azetidines as MEK Inhibitors for the Treatment of Proliferative Diseases - Disclosed are compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof. Such compounds are MEK inhibitors and are useful in the treatment of proliferative diseases, such as cancer. Also disclosed are pharmaceutical compositions containing such compounds as well as methods of using the compounds and compositions of the invention in the treatment of cancer. | 06-18-2009 |
20090163471 | Tropane compounds - A compound according to Formula I or II: | 06-25-2009 |
20090215803 | Pyrimidinones as Casein Kinase II (CK2) Modulators - A compound having Formula (I) or a pharmaceutically acceptable salt thereof, wherein X, R | 08-27-2009 |
20090318373 | Receptor-type kinase modulators and methods of use - The present invention provides compounds for modulating receptor kinase activity, particularly ephrin and EGFR, and methods of treating diseases mediated by receptor kinase activity utilizing the compounds and pharmaceutical compositions thereof. Diseases mediated by receptor kinase activity include, but are not limited to, diseases characterized in part by abnormal levels of cell proliferation (i.e. tumor growth), programmed cell death (apoptosis), cell migration and invasion and angiogenesis associated with tumor growth. Compounds of the invention include “spectrum selective” kinase modulators, compounds that inhibit, regulate and/or modulate signal transduction across subfamilies of receptor-type tyrosine kinases, including ephrin and EGFR. | 12-24-2009 |
20100249096 | Azetidines as MEK Inhibitors for the Treatment of Proliferative Diseases - Disclosed are compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof. Such compounds are MEK inhibitors and are useful in the treatment of proliferative diseases, such as cancer. Also disclosed are pharmaceutical compositions containing such compounds as well as methods of using the compounds and compositions of the invention in the treatment of cancer. | 09-30-2010 |
20100298290 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture - The invention is directed to Compounds of Formula I: | 11-25-2010 |
20100305093 | Inhibitors of mTOR and Methods of Making and Using - The invention is directed to Compounds of Formula I: | 12-02-2010 |
20110071145 | Raf Modulators And Methods Of Use - The present invention relates to compounds of the Formula I, wherein G, A, X1, X2, X3, Z, E, Y, and X are defined herein. The compounds modulate protein kinase enzymatic activity to modulate cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinases, particularly Raf. Methods of using and preparing the compounds, and pharmaceutical compositions thereof, to treat kinase-dependent diseases and conditions are also an aspect of the invention. | 03-24-2011 |
20110263558 | Azetidines as MEK Inhibitors for the Treatment of Proliferative Diseases - Disclosed are compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof. Such compounds are MEK inhibitors and are useful in the treatment of proliferative diseases, such as cancer. Also disclosed are pharmaceutical compositions containing such compounds as well as methods of using the compounds and compositions of the invention in the treatment of cancer. | 10-27-2011 |
20140155418 | Receptor-Type Kinase Modulators and Methods of Use - The present invention provides compounds for modulating receptor kinase activity, particularly ephrin and EGFR, and methods of treating diseases mediated by receptor kinase activity utilizing the compounds and pharmaceutical compositions thereof. Diseases mediated by receptor kinase activity include, but are not limited to, diseases characterized in part by abnormal levels of cell proliferation (i.e. tumor growth), programmed cell death (apoptosis), cell migration and invasion and angiogenesis associated with tumor growth. Compounds of the invention include “spectrum selective” kinase modulators, compounds that inhibit, regulate and/or modulate signal transduction across subfamilies of receptor-type tyrosine kinases, including ephrin and EGFR. | 06-05-2014 |
20140275527 | Azetidines as MEK Inhibitors for the Treatment of Proliferative Diseases - Disclosed are compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof. Such compounds are MEK inhibitors and are useful in the treatment of proliferative diseases, such as cancer. Also disclosed are pharmaceutical compositions containing such compounds as well as methods of using the compounds and compositions of the invention in the treatment of cancer. | 09-18-2014 |